{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:08:14Z","timestamp":1788494894285,"version":"build-2803163510"},"reference-count":119,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.<\/jats:p>","DOI":"10.3390\/ijms25115661","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T03:49:03Z","timestamp":1716436143000},"page":"5661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pancreatic Cancer and Venous Thromboembolism"],"prefix":"10.3390","volume":"25","author":[{"given":"Teagan","family":"Prouse","sequence":"first","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Lorena","family":"Duhaylungsod","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1727-7220","authenticated-orcid":false,"given":"Rinku","family":"Majumder","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-664X","authenticated-orcid":false,"given":"Samarpan","family":"Majumder","sequence":"additional","affiliation":[{"name":"Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1287459","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kothari, A., and Flick, M.J. (2021). Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105138"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26453","DOI":"10.18632\/oncotarget.25458","article-title":"Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process","volume":"9","author":"Faille","year":"2018","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Farge, D., Bournet, B., Conroy, T., Vicaut, E., Rak, J., Zogoulous, G., Barkun, J., Ouaissi, M., Buscail, L., and Frere, C. (2020). Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Cancers, 12.","DOI":"10.3390\/cancers12030618"},{"key":"ref_7","first-page":"342","article-title":"Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment","volume":"50","author":"Costamagna","year":"2023","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4137\/CMO.S18991","article-title":"Cancer-associated thrombosis: An overview","volume":"8","author":"Elyamany","year":"2014","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Glassman, D., Bateman, N.W., Lee, S., Zhao, L., Yao, J., Tan, Y., Ivan, C., Rangel, K.M., Zhang, J., and Conrads, K.A. (2022). Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers, 14.","DOI":"10.3390\/cancers14061496"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chen, J.S., Hung, C.Y., Chang, H., Liu, C.T., Chen, Y.Y., Lu, C.H., Chang, P.H., Hung, Y.S., and Chou, W.C. (2018). Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers, 10.","DOI":"10.3390\/cancers10120501"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1160\/TH16-10-0823","article-title":"Venous thromboembolism: Past, present and future","volume":"117","author":"Schulman","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0043-1778104","article-title":"Cancer-Associated Thrombosis and Beyond: Biomarkers, Treatments, and Cancer-Hemostasis Interactions","volume":"50","author":"Gyldenholm","year":"2024","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/j.gastro.2019.12.009","article-title":"Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes","volume":"158","author":"Frere","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e3472","DOI":"10.1097\/MD.0000000000003472","article-title":"Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","article-title":"Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study","volume":"98","author":"Dickmann","year":"2013","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.trecan.2021.12.008","article-title":"Coagulome and the tumor microenvironment: An actionable interplay","volume":"8","author":"Galmiche","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","article-title":"Cancer-associated thrombosis: Enhanced awareness and pathophysiologic complexity","volume":"21","author":"Falanga","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhang, H., Liao, X., and Tsai, H.I. (2023). KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1147676"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1055\/s-0039-1693472","article-title":"Cancer-Associated Thrombosis: A Two-Way Street","volume":"45","author":"Sharma","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","article-title":"Resection of pancreatic cancer in Europe and USA: An international large-scale study highlighting large variations","volume":"68","author":"Huang","year":"2019","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Willems, R.A.L., Michiels, N., Lanting, V.R., Bouwense, S., van den Broek, B.L.J., Graus, M., Klok, F.A., Groot Koerkamp, B., de Laat, B., and Roest, M. (2023). Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care. Cancers, 15.","DOI":"10.3390\/cancers15143546"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jso.24361","article-title":"Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?","volume":"114","author":"Krepline","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3121\/cmr.2009.866","article-title":"Virchow\u2019s contribution to the understanding of thrombosis and cellular biology","volume":"8","author":"Kumar","year":"2010","journal-title":"Clin. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: Biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","first-page":"429","article-title":"Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer","volume":"50","author":"Willems","year":"2023","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.transci.2010.05.009","article-title":"Red cell changes during storage","volume":"43","author":"Hess","year":"2010","journal-title":"Transfus. Apher. Sci."},{"key":"ref_28","first-page":"204","article-title":"Phosphatidylserine exposure on stored red blood cells as a parameter for donor-dependent variation in product quality","volume":"12","author":"Dinkla","year":"2014","journal-title":"Blood Transfus."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/jth.12677","article-title":"Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells","volume":"12","author":"Semeraro","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3109\/00365529509096346","article-title":"Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines","volume":"30","author":"Heinmoller","year":"1995","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jtha.2023.12.037","article-title":"Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer","volume":"22","author":"Willems","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1165989","DOI":"10.3389\/fimmu.2023.1165989","article-title":"Effects of the interactions between platelets with other cells in tumor growth and progression","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mai, S., and Inkielewicz-Stepniak, I. (2021). Pancreatic Cancer and Platelets Crosstalk: A Potential Biomarker and Target. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.749689"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1158\/1055-9965.EPI-10-0178","article-title":"Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma","volume":"19","author":"Poruk","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"42186","DOI":"10.1038\/srep42186","article-title":"A critical role of platelet TGF-beta release in podoplanin-mediated tumour invasion and metastasis","volume":"7","author":"Takemoto","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00595-017-1559-x","article-title":"Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer","volume":"48","author":"Hirayama","year":"2018","journal-title":"Surg. Today"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/01.CIR.102.16.1931","article-title":"P-selectin expression on platelets determines size and stability of platelet aggregates","volume":"102","author":"Merten","year":"2000","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/ATVBAHA.121.316463","article-title":"Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer","volume":"41","author":"Moik","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1538-7836.2005.01369.x","article-title":"von Willebrand factor: Two sides of a coin","volume":"3","author":"Sadler","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3324\/haematol.2022.281315","article-title":"Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality","volume":"108","author":"Karampinis","year":"2023","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0049-3848(16)30353-X","article-title":"The polyphosphate\/factor XII pathway in cancer-associated thrombosis: Novel perspectives for safe anticoagulation in patients with malignancies","volume":"141","author":"Nickel","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.jtha.2023.06.009","article-title":"Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: A prospective cohort study","volume":"21","author":"Bosch","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Tavares, V., Pinto, R., Assis, J., Pereira, D., and Medeiros, R. (2020). Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. Biochim. Biophys. Acta Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2019.188331"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/jth.13002","article-title":"Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice","volume":"13","author":"Thomas","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"714357","DOI":"10.3389\/fonc.2021.714357","article-title":"The Role of Neutrophil Extracellular Traps in Cancer","volume":"11","author":"Shao","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hassan, N., Efing, J., Kiesel, L., Bendas, G., and Gotte, M. (2023). The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans. Cancers, 15.","DOI":"10.3390\/cancers15051524"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/IGC.0000000000000848","article-title":"Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism","volume":"27","author":"Sakurai","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/ATVBAHA.122.318463","article-title":"Histopathological Features of Cancer-Associated Venous Thromboembolism: Presence of Intrathrombus Cancer Cells and Prothrombotic Factors","volume":"43","author":"Gi","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_50","first-page":"3267","article-title":"Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo","volume":"52","author":"Nierodzik","year":"1992","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrgastro.2013.120","article-title":"Mucins in pancreatic cancer and its microenvironment","volume":"10","author":"Kaur","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2018-04-841585","article-title":"Hypoxia downregulates protein S expression","volume":"132","author":"Pilli","year":"2018","journal-title":"Blood"},{"key":"ref_53","first-page":"1322","article-title":"Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation","volume":"44","author":"Pilli","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0049-3848(08)70021-5","article-title":"Protein S is a cofactor for tissue factor pathway inhibitor","volume":"122","author":"Rosing","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.critrevonc.2013.07.004","article-title":"Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer","volume":"88","author":"Suleiman","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/jth.15025","article-title":"Anticoagulant protein S-New insights on interactions and functions","volume":"18","author":"Gierula","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ni.2986","article-title":"Diversification of TAM receptor tyrosine kinase function","volume":"15","author":"Zagorska","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Blix, K., Jensvoll, H., Braekkan, S.K., and Hansen, J.B. (2013). White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromso study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073447"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e22946","DOI":"10.4161\/onci.22946","article-title":"Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression","volume":"2","author":"Demers","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1134073","DOI":"10.1080\/2162402X.2015.1134073","article-title":"Priming of neutrophils toward NETosis promotes tumor growth","volume":"5","author":"Demers","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jth.12571","article-title":"Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development","volume":"12","author":"Savchenko","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Oto, J., Navarro, S., Larsen, A.C., Solmoirago, M.J., Plana, E., Hervas, D., Fernandez-Pardo, A., Espana, F., Kristensen, S.R., and Thorlacius-Ussing, O. (2020). MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030840"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"103989","DOI":"10.1016\/j.critrevonc.2023.103989","article-title":"Thrombosis and cachexia in cancer: Two partners in crime?","volume":"186","author":"Tavares","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2021.08.002","article-title":"Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer","volume":"207","author":"Groen","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Tavares, V., Neto, B.V., Vilas-Boas, M.I., Pereira, D., and Medeiros, R. (2022). Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence. Biochim. Biophys. Acta Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2022.188778"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: The when, how and why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-12-0789","article-title":"Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer","volume":"106","author":"Menapace","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project","volume":"243","author":"Agnelli","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.21873\/anticanres.16142","article-title":"Prophylactic Anticoagulation in Patients With Pancreatic Adenocarcinoma: A Single Tertiary Care Center Retrospective QI Project","volume":"43","author":"Shah","year":"2023","journal-title":"Anticancer. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.thromres.2018.01.017","article-title":"Hemostatic biomarkers in cancer progression","volume":"164","author":"Falanga","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/jog.15660","article-title":"The role of tissue factor pathway inhibitor 2 in the coagulation and fibrinolysis system","volume":"49","author":"Kobayashi","year":"2023","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5482\/ha-1160","article-title":"Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor","volume":"32","author":"Langer","year":"2012","journal-title":"Hamostaseologie"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"Dahm","year":"2003","journal-title":"Blood"},{"key":"ref_79","first-page":"1128","article-title":"Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer","volume":"109","author":"Englisch","year":"2024","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s40001-023-01379-x","article-title":"Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: A retrospective study","volume":"28","author":"Jiaao","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/bjc.2016.170","article-title":"Tissue factor-bearing microparticles and CA19.9: Two players in pancreatic cancer-associated thrombosis?","volume":"115","author":"Woei","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.21873\/anticanres.16491","article-title":"High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients","volume":"43","author":"Otsu","year":"2023","journal-title":"Anticancer. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"Simanek","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3748\/wjg.v27.i19.2325","article-title":"Burden of venous thromboembolism in patients with pancreatic cancer","volume":"27","author":"Frere","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2017.06.021","article-title":"Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer\u2014A retrospective cohort study","volume":"157","author":"Kruger","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"Franke","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00535-020-01666-y","article-title":"Recent advances in chemotherapy for pancreatic cancer: Evidence from Japan and recommendations in guidelines","volume":"55","author":"Okusaka","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Yamai, T., Ikezawa, K., Hiraga, E., Kawamoto, Y., Hirao, T., Higashi, S., Daiku, K., Maeda, S., Abe, Y., and Urabe, M. (2022). Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264653"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/annonc\/mdm284","article-title":"Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients","volume":"18","author":"Mandala","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","article-title":"Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"77","author":"Ueno","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"101348","DOI":"10.1016\/j.beha.2022.101348","article-title":"A review of latest clinical practice guidelines for the management of cancer-associated thrombosis","volume":"35","author":"Frere","year":"2022","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11239-021-02570-9","article-title":"Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation","volume":"53","author":"Wang","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"Becattini","year":"2022","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1002\/cam4.3269","article-title":"Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study","volume":"9","author":"McNamara","year":"2020","journal-title":"Cancer Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","article-title":"Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: A prospective cohort study","volume":"43","author":"Mantha","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/5584_2016_112","article-title":"The Role of New Oral Anticoagulants (NOACs) in Cancer Patients","volume":"906","author":"Ravikumar","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_109","first-page":"4261","article-title":"Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients","volume":"30","author":"Shaib","year":"2010","journal-title":"Anticancer. Res."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Frere, C., Benzidia, I., Marjanovic, Z., and Farge, D. (2019). Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. Cancers, 11.","DOI":"10.3390\/cancers11010071"},{"key":"ref_111","first-page":"210","article-title":"Translation into French and republication of: \u201cAnticoagulant treatment of cancer-associated thromboembolism\u201d","volume":"45","author":"Mahe","year":"2024","journal-title":"Rev. M\u00e9d. Interne"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Gornicki, T., Buldys, K., Zielinska, D., and Chabowski, M. (2023). Direct-Acting Oral Anticoagulant Therapy in Cancer Patients\u2014A Review. Cancers, 15.","DOI":"10.3390\/cancers15102697"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11239-023-02778-x","article-title":"A retrospective evaluation of direct oral anticoagulant (DOAC) management strategies in patients with cancer on active chemotherapy","volume":"55","author":"Tran","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"26990","DOI":"10.18632\/oncotarget.25454","article-title":"Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: The QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)","volume":"9","author":"Farge","year":"2018","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_117","first-page":"378","article-title":"Pancreatic cancer-associated thrombosis","volume":"29","author":"Tam","year":"2023","journal-title":"Hong Kong Med. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/jth.15519","article-title":"Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J. Thromb. Haemost."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:56Z","timestamp":1760107616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":119,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115661"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115661","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}